C21
Phase 1Small molecule
C21 is one of 53 small molecule programs targeting Endothelial Dysfunction. It is currently in Phase 1.
2
Indications
7
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Activella
Eli LillyPreclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Benadryl
PParkedale
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
C21
VVicore Pharma AB
Phase 1
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Preclinical
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Immunosuppressive
Chiesi Farmaceutici S.p.A.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-193 trials
Endothelial Dysfunction1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C21. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VVicore Pharma AB